Shares of bioAffinity Technologies, Inc. (NASDAQ:BIAF – Get Rating) fell 2.8% during mid-day trading on Tuesday . The company traded as low as $1.52 and last traded at $1.65. 11,254 shares were traded during mid-day trading, a decline of 99% from the average session volume of 1,646,997 shares. The stock had previously closed at $1.70.
bioAffinity Technologies Stock Down 2.8 %
The firm has a 50 day simple moving average of $1.98.
Get bioAffinity Technologies alerts:Institutional Trading of bioAffinity Technologies
A hedge fund recently bought a new stake in bioAffinity Technologies stock. Citadel Advisors LLC bought a new stake in bioAffinity Technologies, Inc. (NASDAQ:BIAF – Get Rating) during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 20,583 shares of the company's stock, valued at approximately $60,000. Citadel Advisors LLC owned approximately 0.75% of bioAffinity Technologies at the end of the most recent quarter. Institutional investors and hedge funds own 2.43% of the company's stock.
bioAffinity Technologies Company Profile
(Get Rating)
bioAffinity Technologies, Inc, a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat cancer at the cellular level.
Featured Articles
- Get a free copy of the StockNews.com research report on bioAffinity Technologies (BIAF)
- Monoclonal Antibodies? Avid Bioservices surges 32% on Blowout Q3
- GitLab Crashes On Guidance; Analysts Defend
- Healthcare Stocks With at Least 30 Years of Dividend Increases
- Coinbase Pops As SVB Crumbles To Dust
- Airlines Update Guidance, Shares Head For Different Destinations
Receive News & Ratings for bioAffinity Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bioAffinity Technologies and related companies with MarketBeat.com's FREE daily email newsletter.